KR20110061624A - Ｃ형 간염 항체 및 이의 용도 - Google Patents

Ｃ형 간염 항체 및 이의 용도 Download PDF

Info

Publication number
KR20110061624A
KR20110061624A KR1020117008883A KR20117008883A KR20110061624A KR 20110061624 A KR20110061624 A KR 20110061624A KR 1020117008883 A KR1020117008883 A KR 1020117008883A KR 20117008883 A KR20117008883 A KR 20117008883A KR 20110061624 A KR20110061624 A KR 20110061624A
Authority
KR
South Korea
Prior art keywords
hcv
antibody
antibodies
epitopes
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117008883A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 퐁
젠-용 켁크
Original Assignee
더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티 filed Critical 더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티
Publication of KR20110061624A publication Critical patent/KR20110061624A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020117008883A 2008-10-05 2008-10-05 Ｃ형 간염 항체 및 이의 용도 Withdrawn KR20110061624A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/078884 WO2010039154A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20110061624A true KR20110061624A (ko) 2011-06-09

Family

ID=42073762

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117008883A Withdrawn KR20110061624A (ko) 2008-10-05 2008-10-05 Ｃ형 간염 항체 및 이의 용도

Country Status (12)

Country Link
US (1) US8858947B2 (https=)
EP (1) EP2331573A4 (https=)
JP (1) JP2012504602A (https=)
KR (1) KR20110061624A (https=)
CN (1) CN102197050A (https=)
AU (1) AU2008362482A1 (https=)
BR (1) BRPI0823197A2 (https=)
CA (1) CA2738644A1 (https=)
EA (1) EA201170353A1 (https=)
IL (1) IL212040A0 (https=)
MX (1) MX2011003613A (https=)
WO (1) WO2010039154A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034891A1 (en) * 2014-09-05 2016-03-10 Medical Research Council Anti-hepatitis c antibodies and antigen binding fragments thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2495256A4 (en) * 2009-10-30 2013-09-25 Toray Industries ANTIBODIES WITH HEMMETAL EFFECT ON INFECTIONS WITH HEPATITIS C VIRUS (HCV) AND ITS USE
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
EP2705150B1 (en) * 2011-05-02 2020-07-29 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
MX366886B (es) 2012-08-07 2019-07-30 Massachusetts Inst Technology Anticuerpos anti-virus del dengue y usos de los mismos.
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
KR20160119806A (ko) 2014-02-11 2016-10-14 메사추세츠 인스티튜트 오브 테크놀로지 신규한 온전한 범위의 항-뎅기 항체
WO2015133467A1 (ja) * 2014-03-06 2015-09-11 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN109641955B (zh) * 2016-03-22 2022-07-08 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
CN107011435B (zh) * 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
EP4095156A1 (en) * 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1462300A (en) * 1998-11-05 2000-05-22 Board Of Trustees Of The Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034891A1 (en) * 2014-09-05 2016-03-10 Medical Research Council Anti-hepatitis c antibodies and antigen binding fragments thereof

Also Published As

Publication number Publication date
AU2008362482A1 (en) 2010-04-08
IL212040A0 (en) 2011-06-30
WO2010039154A1 (en) 2010-04-08
JP2012504602A (ja) 2012-02-23
EP2331573A4 (en) 2012-09-05
US8858947B2 (en) 2014-10-14
MX2011003613A (es) 2011-08-03
BRPI0823197A2 (pt) 2015-06-23
EA201170353A1 (ru) 2011-12-30
CN102197050A (zh) 2011-09-21
US20120039846A1 (en) 2012-02-16
EP2331573A1 (en) 2011-06-15
CA2738644A1 (en) 2010-05-08

Similar Documents

Publication Publication Date Title
KR20110061624A (ko) Ｃ형 간염 항체 및 이의 용도
JP6993401B2 (ja) 抗ジカ（ｚｉｋａ）ウイルス抗体およびその使用方法
Tarr et al. An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission
US6951646B1 (en) Anti hepatitis C virus antibody and uses thereof
KR101518081B1 (ko) Ｃ형 간염 바이러스(ｈｃｖ)에 대한 인간 항체 및 이것의 용도
JP5698137B2 (ja) Ｃ型肝炎ウイルス感染の阻害のためのモノクローナル抗クローディン１抗体
US20240050565A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
KR20220158053A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체
US20070042359A1 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
CN113354732A (zh) 针对埃博拉病毒糖蛋白的人抗体
EA034767B1 (ru) Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения
KR20180012245A (ko) 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
TW201242613A (en) Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US20150118242A1 (en) Hepatitis c virus neutralizing antibody
KR20110096591A (ko) Ｈｃｖ 감염의 치료적 처리 및 예방을 위한 의약으로서 항 ｈｃｖ 모노클로날 항체
US20100104555A1 (en) HCV neutralizing epitopes
JP2006504645A (ja) 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療
WO2010047829A1 (en) Mutant hepatitis c virus e2 polypeptides for hcv treatment
CN103429265A (zh) 用于治疗和预防hcv感染的抗包膜抗体和抗受体抗体组合物
US12037384B2 (en) Human monoclonal antibodies against yellow fever virus and uses therefor
WO2014065822A1 (en) Hepatitis c virus neutralizing epitopes, antibodies, and methods

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000